Oct 09th 2012 - Edison Investment Research today published a report on Oxford BioMedica (OXB.L, LSE:OXB, LON:OXB) entitled "Outlook Improving...". In summary, the report says:
The recent fund-raising, coupled with the Sanofi opt-in payment, means Oxford BioMedica is well funded and permits the development of its flexible LentiVector gene-delivery technology through to several value inflection points. ProSavin, to correct the dopamine depletion of Parkinson’s disease, may be the most advanced project, but it is the earlier-stage ocular programmes that elicit most interest. The promising data means management is increasingly prioritising this area and re-positioning the business accordingly.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »